The Company was formed in July 1997 to commercialise a range of medical polyurethanes for medical implants developed by the Cooperative Research Centre for Cardiac Technology. The Company owns all of the intellectual property to exploit Elast-Eon TM polyurethanes. AorTech Biomaterials is now in the second phase of technology development. The first phase involved 9 years of basic research into biostable polyurethanes. This has demonstrated the feasibility of the technology and established a proprietary position.
Board members have wide experience in international marketing, finance and technology management.
Professor David Williams, the chairman of the Board also chairs the Company's Scientific Advisory Committee . The Board has established a number of committees to facilitate management and decision making. Michael has extensive experience in biomaterial and device development resulting in seven patents. Additional experience includes regulatory and quality system requirements for implantable medical devices and product introduction into the international market place gained in several roles over his 19 years with Telectronics. He has also had experience in intellectual property management, strategic planning and business development, gained during his secondment to the Cooperative Research Centre for Cardiac Technology, where he served as the Deputy Director and the Chair of the Commercialisation Committee.